Cord Blood News Volume 2.13 | Apr 8 2010

May 12, 2022

131

Cord Blood News 2.13, April 8, 2010.

In this issue: Science News | Current Publications | Industry News | Policy News | Events

Generation of Induced Pluripotent Stem Cells from Human Cord Blood Cells with Only Two Factors: Oct4 and Sox2
Researchers present a detailed protocol for the derivation of cord blood stem cells and how they can be reprogrammed to pluripotency by retroviral transduction with only two factors (OCT4 and SOX2) in two weeks and without the need for additional chemical compounds. [Nat Protoc]

Enumerate total hematopoietic progenitors (CFC) in cord blood units in only 7 days with MethoCult^® Express
by STEMCELL Technologies

REQUEST A SAMPLE

SCIENCE NEWS

Stem Cells from Menstrual Blood May Benefit Stroke Patients
Cryo-Cell International, Inc. announced results of a study published recently showing that stem cells found in menstrual blood may one day be a potential source for stem cell therapies in stroke and other central nervous system disorders. [Press release from Cryo-Cell International, Inc. discussing online prepublication in Stem Cells and Development]

Become an expert at colony identification
Hematopoietic Progenitor Assay Training Course
by STEMCELL Technologies

REGISTER HERE

CURRENT PUBLICATIONS

High-Dose Therapy and Autologous Stem Cell Transplantation in Waldenström Macroglobulinemia: The Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
The aim of this study was to analyze the results of autologous stem cell transplantation in patients with Waldenström macroglobulinemia and to determine the prognostic factors that have a significant impact on outcome. [J Clin Oncol]

Bone Marrow Graft-Versus-Host Disease: Early Destruction of Hematopoietic Niche Following MHC-Mismatched Hematopoietic Stem Cell Transplantation
This study provided evidence of bone marrow (BM) graft-versus-host disease (GVHD); with the identification of osteoblasts as the main target for GVHD in BM. Moreover, the data showed the potential for monoclonal antibody therapies to enhance immune reconstitution in vivo for patients undergoing allogeneic hematopoietic stem cell transplantation. [Blood]

Glutathione S-Transferase T1-Null Seems to be Associated with Graft Failure in Hematopoietic Stem Cell Transplantation
The data suggest that when glutathione S-transferase theta-1 (GSTT1)-null patients are transplanted with a GSTT1-positive graft, rejection due to an antibody-mediated immune response against GSTT1 displayed on transplanted stem cells may take place. [Bone Marrow Transplant]

Functional Module Analysis Reveals Differential Osteogenic and Stemness Potentials in Human Mesenchymal Stem Cells from Bone Marrow and Wharton’s Jelly of Umbilical Cord
Investigators compared the gene expression profiles, enriched canonical pathways and genetic networks of bone marrow mesenchymal stem cells and Wharton’s jelly matrix of umbilical cord mesenchymal stem cells. [Stem Cells Dev]

Human Hematopoietic Stem Cells Express Oct4 Pseudogenes and Lack the Ability to Initiate Oct4 Promoter-Driven Gene Expression
The focus of this work was to corroborate reports that Oct4 is involved in the regulation of adult stem cell self-renewal and differentiation, using a combination of methodologies to rule out pseudogene interference. [J Negat Results Biomed]

Notch Signaling: A Novel Regulating Differentiation Mechanism of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells into Insulin-Producing Cells In Vitro
This study investigated whether Notch signaling could regulate the insulin producing cells differentiation of human umbilical cord blood-derived mesenchymal stem cells. [Chin Med J]

INDUSTRY NEWS

Cerus and Oxford Finance Corporation Enter into $10 Million Growth Capital Credit Facility
Cerus Corporation announced that it has secured a $10 million growth capital credit facility from Oxford Finance Corporation. The credit facility is secured by Cerus’ assets other than intellectual property. [Cerus Corporation Press Release]

Cord Blood America Discusses China, Annual Financial Report
Cord Blood America, Inc.’s CEO and co-founder, Matthew Schissler, in an interview with analyst Francis Gaskins, discussed their recent announcement to build the world’s largest stem cell storage facility in China, in conjunction with AXM Pharma, Inc. [Cord Blood America, Inc. Press Release]

FamilyCord Announces Asset Acquisition of Vista Cord in the Southeast
FamilyCord, a subsidiary of California Cryobank, announced the recent asset acquisition of Vista Cord, a regional cord blood bank primarily servicing the southern U.S. states. [FamilyCord Press Release]

AllCells LLC Announces Facilities Expansion
AllCells LLC recently announced it has completed its expansion into 10,000 additional square feet of office and laboratory production space located in Emeryville, California. [AllCells LLC Press Release]

Blood is Big Business: Why Does it Cost So Much?
Officials of competing blood banks recently opened a portion of their books to the Orlando Sentinel, offering an unprecedented look at the money that’s spent and made to provide a life-saving product to people of all ages. [Orlando Sentinel]

POLICY NEWS

State Looks to Establish Public Cord Blood Bank
A state mandate that requires health care providers to notify pregnant patients of the option to bank or donate placenta/umbilical cord blood has sparked a dialogue on establishing a public umbilical cord blood bank in Connecticut. [Connecticut Senate, United States]

Key Budget Question: $12.4 Million or $6.2 Million for Stem Cell Funding?
A General Assembly budget conference committee started discussions recently to seek a resolution on how much to allocate for stem cell research grants in fiscal 2011, with the House and Senate versions on the legislation far apart. [United States General Assembly, United States]

Enhancing Peer Review: Updated Processes for the Review of All Ruth L. Kirschstein National Research Service Award Fellowship Applications (NOT-OD-10-071) [National Institutes of Health, United States]

NIH Will Require the Electronic Submission of Appointment Forms and Termination Notices via xTrain for Research Training, Fellowship, Education, and Career Awards Beginning January 2011 (NOT-OD-10-072) [National Institutes of Health, United States]

Small Business Innovation Research Award Levels Adjusted to $150,000 (Phase I) and $1,000,000 (Phase II) (NOT-OD-10-079) [National Institutes of Health, United States]

Notice of Change in Expiration Date for Program Announcement on Bioengineering Research Partnerships (PAR-07-352) (NOT-EB-10-001) [National Institutes of Health, United States]

2010 Biological License Application Supplement Noteworthy Approvals [Center for Biologics Evaluation and Research, United States]

Revision of the Requirements for Constituent Materials [Docket No. FDA-2010-N-0099] [Food and Drug Administration, United States]

Voting and Nonvoting Consumer Representative Members on Public Advisory Committees and Panels; Notice of Public Meeting [Docket No. FDA-2010-N-0001] [Food and Drug Administration, United States]

Determination of Regulatory Review Period for Purposes of Patent Extension; LUSEDRA [Docket Nos. FDA-2009-E-0202 and FDA-2009-E-0204] [Food and Drug Administration, United States]

Revision of Organization and Conforming Changes to Regulations [Docket No. FDA-2010-N-0148] [Food and Drug Administration, United States]

Administrative Practices and Procedures; Good Guidance Practices; Technical Amendment [Docket No. FDA-1999-N-3539] [Food and Drug Administration, United States]

EVENTS

American Association for Cancer Research (AACR) 101st Annual Meeting 2010
April 17-21, 2010
Washington, DC, United States